Sofosbuvir-Velpatasvir-Voxilaprevir in G/P Failure

Source: Pearlman B, et al. Am J Gastroenterol. 2019;114:1550-2.

Sofosbuvir-Velpatasvir-Voxilaprevir in G/P-experienced GT 1a and 3 Study Features

- **Design**: Open-label, single-arm, prospective study to evaluate the efficacy of a fixed-dose combination of sofosbuvir-velpatasvir-voxilaprevir for 12 weeks in adults with chronic HCV infection and a history of treatment failure with glecaprevir-pibrentasvir
- **Setting**: 3 medical centers in United States
- **Entry Criteria**
  - Age >18 years
  - Chronic HCV infection
  - Documented virologic failure following glecaprevir-pibrentasvir
  - Chart confirmed to have good adherence to above
- **Primary End Point**: SVR12

Source: Pearlman B, et al. Am J Gastroenterol. 2019;114:1550-52.

Sofosbuvir-Velpatasvir-Voxilaprevir in G/P-experienced GT 1a and 3 Study Design



Abbreviations: G/P, glecaprevir-pibrentasvir; SOF, sofosbuvir; VEL, velpatasvir; VOX = voxilaprevir

Drug Dosing: SOF-VEL-VOX (400/100/100 mg): fixed dose combination; one pill once daily

Source: Pearlman B, et al. Am J Gastroenterol. 2019;114:1550-2.

Sofosbuvir-Velpatasvir-Voxilaprevir in in G/P-experienced GT 1a and 3 Baseline Characteristics

Baseline Characteristic	SOF-VEL-VOX x 12 weeks (n = 31)
Male, n (%)	22 (77)
No prior treatment before G/P, n (%)	28 (90)
Black, n (%)	16 (52)
Cirrhosis, n (%)	18 (58)
Genotype 1a, n (%) Cirrhosis Prior relapse	13 (42) 6/13 13/13
Genotype 3a, n (%) Cirrhosis Prior relapse Prior breakthrough	18 (58) 12/18 15/18 3/18
Baseline RAS, n (%) None NS5a only NS3 only NS5a and NS3	28 (90) 3 (10) 14 (50) 3 (10) 11 (40)

Abbreviations: G/P, glecaprevir-pibrentasvir; RAS, resistance-associated substitution; NS, non-structural

Source: Pearlman B, et al. Am J Gastroenterol. 2019;114:1550-2.

Sofosbuvir-Velpatasvir-Voxilaprevir in in G/P-experienced GT 1a and 3 Results



Abbreviations: RAS, baseline resistance-associated substitution; GT, genotype

Source: Pearlman B, et al. Am J Gastroenterol. 2019;114:1550-2.

Sofosbuvir-Velpatasvir-Voxilaprevir in in G/P-experienced GT 1a and 3 Conclusions

Conclusion: “In conclusion, SOF/VEL/VOX once daily for 12 weeks is safe and effective for GT 1- and 3-chronically infected HCV patients who have failed G/P therapy.”

Source: Pearlman B, et al. Am J Gastroenterol. 2019;114:1550-2.

Acknowledgments

Hepatitis C Online is funded by a cooperative agreement from the Centers for Disease Control and Prevention (CDC-RFA- PS21-2105). This project is led by the University of Washington Infectious Diseases Education and Assessment (IDEA) Program.

HEPATITIS B ONLINE

HEPATITIS C ONLINE

IDEA INFECTIOUS DISEASES EDUCATION & ASSESSMENT